What is the current valuation of the Adeno-associated Virus (AAV) Vector-based Gene Therapy Market?

The market valuation was 5.718 USD Billion in 2024. Read More

What is the projected market size for the AAV Vector-based Gene Therapy Market by 2035?

The projected valuation for 2035 is 70.67 USD Billion. Read More

What is the expected CAGR for the AAV Vector-based Gene Therapy Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 25.68%. Read More

Which disease types are leading in the AAV Vector-based Gene Therapy Market?

Hematological malignancies and neurological disorders are leading, with valuations of 18.0 and 15.0 USD Billion, respectively. Read More

What are the key vector serotypes in the AAV Vector-based Gene Therapy Market?

AAV8 and AAV2 are key serotypes, with projected valuations of 18.0 and 15.0 USD Billion, respectively. Read More

How does the administration route impact the AAV Vector-based Gene Therapy Market?

Intravenous administration is projected to lead with a valuation of 18.0 USD Billion. Read More

Who are the major players in the AAV Vector-based Gene Therapy Market?

Key players include Spark Therapeutics, Bayer AG, Novartis AG, and Bristol-Myers Squibb. Read More

What is the market performance of oncology within the AAV Vector-based Gene Therapy Market?

Oncology is projected to reach a valuation of 15.67 USD Billion. Read More

How do the projected growth rates vary among different disease types in the AAV Vector-based Gene Therapy Market?

Hematological malignancies and neurological disorders show the highest growth potential, indicating robust market dynamics. Read More

What implications do the growth projections have for investment in the AAV Vector-based Gene Therapy Market?

The substantial projected growth suggests a favorable environment for investment, particularly from leading companies. Read More

Adeno Associated Virus Aav Vector Based Gene Therapy Market

Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Research Report: Size, Share, Trend Analysis By Disease Type (Hematological Malignancies, Neurological Disorders, Cardiovascular Diseases, Ophthalmic Diseases, Oncology), By Vector Serotype (AAV1, AAV2, AAV5, AAV6, AAV8, AAV9), By Administration Route (Intravenous, Intramuscular, Subcutaneous, Intraocular, Intracerebral) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

25.68%

2024 Market Size

$ 5.72 Billion

2035 Market Size

$ 70.67 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/27946-HCR | Pages: 128 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Disease Type (USD Billion) | |
  1. 4.1.1 Hematological Malignancies | |
  2. 4.1.2 Neurological Disorders | |
  3. 4.1.3 Cardiovascular Diseases | |
  4. 4.1.4 Ophthalmic Diseases | |
  5. 4.1.5 Oncology |
2. 4.2 Healthcare, BY Vector Serotype (USD Billion) | |
  1. 4.2.1 AAV1 | |
  2. 4.2.2 AAV2 | |
  3. 4.2.3 AAV5 | |
  4. 4.2.4 AAV6 | |
  5. 4.2.5 AAV8 | |
  6. 4.2.6 AAV9 |
3. 4.3 Healthcare, BY Administration Route (USD Billion) | |
  1. 4.3.1 Intravenous | |
  2. 4.3.2 Intramuscular | |
  3. 4.3.3 Subcutaneous | |
  4. 4.3.4 Intraocular | |
  5. 4.3.5 Intracerebral |
4. 4.4 Healthcare, BY Region (USD Billion) | |
  1. 4.4.1 North America | | |
    1. 4.4.1.1 US | | |
    2. 4.4.1.2 Canada | |
  2. 4.4.2 Europe | | |
    1. 4.4.2.1 Germany | | |
    2. 4.4.2.2 UK | | |
    3. 4.4.2.3 France | | |
    4. 4.4.2.4 Russia | | |
    5. 4.4.2.5 Italy | | |
    6. 4.4.2.6 Spain | | |
    7. 4.4.2.7 Rest of Europe | |
  3. 4.4.3 APAC | | |
    1. 4.4.3.1 China | | |
    2. 4.4.3.2 India | | |
    3. 4.4.3.3 Japan | | |
    4. 4.4.3.4 South Korea | | |
    5. 4.4.3.5 Malaysia | | |
    6. 4.4.3.6 Thailand | | |
    7. 4.4.3.7 Indonesia | | |
    8. 4.4.3.8 Rest of APAC | |
  4. 4.4.4 South America | | |
    1. 4.4.4.1 Brazil | | |
    2. 4.4.4.2 Mexico | | |
    3. 4.4.4.3 Argentina | | |
    4. 4.4.4.4 Rest of South America | |
  5. 4.4.5 MEA | | |
    1. 4.4.5.1 GCC Countries | | |
    2. 4.4.5.2 South Africa | | |
    3. 4.4.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Spark Therapeutics (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bayer AG (DE) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Novartis AG (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Bristol-Myers Squibb (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 GSK (GB) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Pfizer Inc. (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sarepta Therapeutics (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Astellas Pharma Inc. (JP) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 UniQure N.V. (NL) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY DISEASE TYPE |
7. 6.4 US MARKET ANALYSIS BY VECTOR SEROTYPE |
8. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE |
9. 6.6 CANADA MARKET ANALYSIS BY DISEASE TYPE |
10. 6.7 CANADA MARKET ANALYSIS BY VECTOR SEROTYPE |
11. 6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
12. 6.9 EUROPE MARKET ANALYSIS |
13. 6.10 GERMANY MARKET ANALYSIS BY DISEASE TYPE |
14. 6.11 GERMANY MARKET ANALYSIS BY VECTOR SEROTYPE |
15. 6.12 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
16. 6.13 UK MARKET ANALYSIS BY DISEASE TYPE |
17. 6.14 UK MARKET ANALYSIS BY VECTOR SEROTYPE |
18. 6.15 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
19. 6.16 FRANCE MARKET ANALYSIS BY DISEASE TYPE |
20. 6.17 FRANCE MARKET ANALYSIS BY VECTOR SEROTYPE |
21. 6.18 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
22. 6.19 RUSSIA MARKET ANALYSIS BY DISEASE TYPE |
23. 6.20 RUSSIA MARKET ANALYSIS BY VECTOR SEROTYPE |
24. 6.21 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
25. 6.22 ITALY MARKET ANALYSIS BY DISEASE TYPE |
26. 6.23 ITALY MARKET ANALYSIS BY VECTOR SEROTYPE |
27. 6.24 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
28. 6.25 SPAIN MARKET ANALYSIS BY DISEASE TYPE |
29. 6.26 SPAIN MARKET ANALYSIS BY VECTOR SEROTYPE |
30. 6.27 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
31. 6.28 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE |
32. 6.29 REST OF EUROPE MARKET ANALYSIS BY VECTOR SEROTYPE |
33. 6.30 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
34. 6.31 APAC MARKET ANALYSIS |
35. 6.32 CHINA MARKET ANALYSIS BY DISEASE TYPE |
36. 6.33 CHINA MARKET ANALYSIS BY VECTOR SEROTYPE |
37. 6.34 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
38. 6.35 INDIA MARKET ANALYSIS BY DISEASE TYPE |
39. 6.36 INDIA MARKET ANALYSIS BY VECTOR SEROTYPE |
40. 6.37 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
41. 6.38 JAPAN MARKET ANALYSIS BY DISEASE TYPE |
42. 6.39 JAPAN MARKET ANALYSIS BY VECTOR SEROTYPE |
43. 6.40 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
44. 6.41 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE |
45. 6.42 SOUTH KOREA MARKET ANALYSIS BY VECTOR SEROTYPE |
46. 6.43 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
47. 6.44 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE |
48. 6.45 MALAYSIA MARKET ANALYSIS BY VECTOR SEROTYPE |
49. 6.46 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
50. 6.47 THAILAND MARKET ANALYSIS BY DISEASE TYPE |
51. 6.48 THAILAND MARKET ANALYSIS BY VECTOR SEROTYPE |
52. 6.49 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE |
53. 6.50 INDONESIA MARKET ANALYSIS BY DISEASE TYPE |
54. 6.51 INDONESIA MARKET ANALYSIS BY VECTOR SEROTYPE |
55. 6.52 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
56. 6.53 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE |
57. 6.54 REST OF APAC MARKET ANALYSIS BY VECTOR SEROTYPE |
58. 6.55 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE |
59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
60. 6.57 BRAZIL MARKET ANALYSIS BY DISEASE TYPE |
61. 6.58 BRAZIL MARKET ANALYSIS BY VECTOR SEROTYPE |
62. 6.59 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE |
63. 6.60 MEXICO MARKET ANALYSIS BY DISEASE TYPE |
64. 6.61 MEXICO MARKET ANALYSIS BY VECTOR SEROTYPE |
65. 6.62 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE |
66. 6.63 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE |
67. 6.64 ARGENTINA MARKET ANALYSIS BY VECTOR SEROTYPE |
68. 6.65 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE |
70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY VECTOR SEROTYPE |
71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
72. 6.69 MEA MARKET ANALYSIS |
73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE |
74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY VECTOR SEROTYPE |
75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE |
76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE |
77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY VECTOR SEROTYPE |
78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
79. 6.76 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE |
80. 6.77 REST OF MEA MARKET ANALYSIS BY VECTOR SEROTYPE |
81. 6.78 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
83. 6.80 RESEARCH PROCESS OF MRFR |
84. 6.81 DRO ANALYSIS OF HEALTHCARE |
85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
88. 6.85 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE) |
89. 6.86 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion) |
90. 6.87 HEALTHCARE, BY VECTOR SEROTYPE, 2024 (% SHARE) |
91. 6.88 HEALTHCARE, BY VECTOR SEROTYPE, 2024 TO 2035 (USD Billion) |
92. 6.89 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
93. 6.90 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
95. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) |
125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
126. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Adeno Associated Virus Aav Vector Based Gene Therapy Market Segmentation

Adeno Associated Virus Aav Vector Based Gene Therapy Market By Disease Type (USD Billion, 2025-2035)

Hematological Malignancies
Neurological Disorders
Cardiovascular Diseases
Ophthalmic Diseases
Oncology

Adeno Associated Virus Aav Vector Based Gene Therapy Market By Vector Serotype (USD Billion, 2025-2035)

AAV1
AAV2
AAV5
AAV6
AAV8
AAV9

Adeno Associated Virus Aav Vector Based Gene Therapy Market By Administration Route (USD Billion, 2025-2035)

Intravenous
Intramuscular
Subcutaneous
Intraocular
Intracerebral

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”